Fecal Microbial Transplant Effect on Clinical Outcomes and Fecal Microbiome in Active Crohnʼs Disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Crohn's disease (CD) is a chronic idiopathic inflammatory intestinal disorder associated with fecal dysbiosis. Fecal microbial transplant (FMT) is a potential therapeutic option for individuals with CD based on the hypothesis that changing the fecal dysbiosis could promote less intestinal inflammation. METHODS: Nine patients, aged 12 to 19 years, with mild-to-moderate symptoms defined by Pediatric Crohn's Disease Activity Index (PCDAI of 10-29) were enrolled into a prospective open-label study of FMT in CD (FDA IND 14942). Patients received FMT by nasogastric tube with follow-up evaluations at 2, 6, and 12 weeks. PCDAI, C-reactive protein, and fecal calprotectin were evaluated at each study visit. RESULTS: All reported adverse events were graded as mild except for 1 individual who reported moderate abdominal pain after FMT. All adverse events were self-limiting. Metagenomic evaluation of stool microbiome indicated evidence of FMT engraftment in 7 of 9 patients. The mean PCDAI score improved with patients having a baseline of 19.7 ± 7.2, with improvement at 2 weeks to 6.4 ± 6.6 and at 6 weeks to 8.6 ± 4.9. Based on PCDAI, 7 of 9 patients were in remission at 2 weeks and 5 of 9 patients who did not receive additional medical therapy were in remission at 6 and 12 weeks. No or modest improvement was seen in patients who did not engraft or whose microbiome was most similar to their donor. CONCLUSIONS: This is the first study to demonstrate that FMT for CD may be a possible therapeutic option for CD. Further prospective studies are required to fully assess the safety and efficacy of the FMT in patients with CD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“UC patients were much less likely to achieve clinical remission (22%).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [73]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, the remission rate fell to 36.2% when the case series were excluded in order to minimize publication bias.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [73]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A recent systematic review and meta-analysis of 18 studies that included 122 patients with IBD who received FMT found a 45% clinical remission rate.73”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [73]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“This review also found that although FMT was not associated with any serious adverse events during short-term follow up, a number of patients experienced fever, chills, and gastrointestinal symptoms including bloating, flatulence, vomiting, diarrhea, and abdominal tenderness.73”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [73]
In the citing paper
“The pooled estimates were highest in younger patients (7–20 years old) and in patients with Crohn’s disease, with 64.1% and 60.5% achieving clinical remission, respectively.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706625104 · Cited by 4,611
Metagenomic microbial community profiling using unique clade-specific marker genes
Segata, N., Waldron, L., Ballarini, A., Narasimhan, V., Jousson, O., & Huttenhower, C. (2012) · Nature Methods · doi:10.1038/nmeth.2066 · Cited by 1,776
Sartor, R. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.024 · Cited by 1,052
Treating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
(1958) · PubMed · Cited by 978
Wang, W., Chen, L., Zhou, R., Wang, X., Song, L., Huang, S., Wang, G., & Xia, B. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01500-13 · Cited by 509 · cited 8×
“This divergence from healthy individual’s fecal microbiota is characterized by a decrease in commensal bacteria including members of Firmicutes and Bacteroides as well as a relative increase in proinflammatory bacteria such as Enterobacteriaceae.1,2 In addition, a decrease in butyrate-producing bacterium that is impor…”
ResultInfluentialAntibiotic Exposure and IBD Development Among Children: A Population-Based Cohort Study
Kronman, M. P., Zaoutis, T. E., Haynes, K., Feng, R., & Coffin, S. E. (2012) · Pediatrics · doi:10.1542/peds.2011-3886 · Cited by 445
Mucosal and Invading Bacteria in Patients with Inflammatory Bowel Disease Compared with Controls
Kleessen, B., Kroesen, A. J., Buhr, H. J., & Blaut, M. (2002) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655202320378220 · Cited by 351
Evaluation of the Pediatric Crohn Disease Activity Index: A Prospective Multicenter Experience
Hyams, J., Markowitz, J., Otley, A., Rosh, J., Mack, D., Bousvaros, A., Kugathasan, S., Pfefferkorn, M., Tolia, V., Evans, J., et al. (2005) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/01.mpg.0000183350.46795.42 · Cited by 328
Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease
Fujimoto, T., Imaeda, H., Takahashi, K., Kasumi, E., Bamba, S., Fujiyama, Y., & Andoh, A. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12073 · Cited by 304 · cited 3×
“prausnitzii, as well as an increase in Proteobacteria, although the actual significance of these species-based alterations is only correlative and therefore is functionally unknown.(1,2) Numerous clinical studies have attempted to modulate the fecal microbiome to decrease the inflammatory immune response using prebiot…”
Background
Cited by
Gut microbiota and IBD: causation or correlation?
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.88 · Cited by 1,778
Host–microbiota interactions in inflammatory bowel disease
Caruso, R., Lo, B. C., & Núñez, G. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0268-7 · Cited by 780
Factors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
Fecal microbiota transplantation: in perspective
Gupta, S., Allen-Vercoe, E., & Petrof, E. O. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15607414 · Cited by 481
Metadata
- Authors
- Suskind, D. L., Brittnacher, M. J., Wahbeh, G., Shaffer, M. L., Hayden, H. S., Qin, X., Singh, N., Damman, C. J., Hager, K. R., Nielson, H., & Miller, S. I.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Seattle Children's Hospital (US)
- University of Washington (US)
- Corresponding author
- Suskind, David L.
- ORCID
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03
- Volume
- 21
- Issue
- 3
- Pages
- 556-563
- ISSN
- 1078-0998 (ISSN-L)
- PMC
- PMC4329080
- OpenAlex
- W1993235214
- Cited by
- 243
- References
- 17
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 12 · 2023: 20 · 2022: 24 · 2021: 26 · 2020: 24 · 2019: 22 · 2018: 36 · 2017: 26 · 2016: 22 · 2015: 12
- FWCI
- 21.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Inflammatory Bowel Diseases (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000423, KL2TR000421)
- Center for Clinical and Translational Research
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK089507)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, Crohn's disease
- MeSH terms
- Adolescent, Adult, Biological Therapy, Child, Crohn Disease, Feces, Female, Humans, Male, Prognosis, Computational Biology, Metagenome, Young Adult, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fecal Microbial Transplant Effect on Clinical Outcomes and Fecal Microbiome in Active Crohnʼs Disease. https://app.cochat.ai/papers/10.1097/mib.0000000000000307
- The paper
- Suskind, D. L., Brittnacher, M. J., Wahbeh, G., Shaffer, M. L., Hayden, H. S., Qin, X., Singh, N., Damman, C. J., Hager, K. R., Nielson, H., & Miller, S. I. (2015). Fecal Microbial Transplant Effect on Clinical Outcomes and Fecal Microbiome in Active Crohnʼs Disease. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0000000000000307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.